📗 Cite This Artifact
GHK-Cu — Copper-Binding Tripeptide
GHK-Cu — Copper-Binding Tripeptide
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GHK-Cu — Copper-Binding Tripeptide</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Pickart et al. (2015)</td>
<td>In vitro</td>
</tr>
<tr>
<td class="label">van Heemst et al. (2022)</td>
<td>Mouse AD model</td>
</tr>
<tr>
<td class="label">Campisi et al. (2019)</td>
<td>Mouse aging</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Dose Range</td>
</tr>
<tr>
<td class="label">Topical</td>
<td>0.5-2% solution</td>
</tr>
<tr>
<td class="label">Subcutaneous</td>
<td>1-2 mg</td>
</tr>
<tr>
<td class="label">Intranasal (research)</td>
<td>0.5-1 mg</td>
</tr>
<tr>
<td class="label">Oral</td>
<td>2-5 mg</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Copper supplements</td>
<td>Potential copper overload</td>
</tr>
<tr>
<td class="label">Chelators (EDTA)</td>
<td>May reduce GHK-Cu efficacy</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>Potential synergy</td>
</tr>
</table>
Path: /therapeutics/ghk-cu Also Known As: Copper tripeptide, GHK-Cu, GHK-Copper Chemical Formula: C_14H_24N_6O_4Cu Sequence: Gly-Lys-Lys (with Cu²⁺ ion) Molecular Weight: ~403 Da (peptide), ~466 Da (with copper)
Overview
...GHK-Cu — Copper-Binding Tripeptide
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GHK-Cu — Copper-Binding Tripeptide</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Pickart et al. (2015)</td>
<td>In vitro</td>
</tr>
<tr>
<td class="label">van Heemst et al. (2022)</td>
<td>Mouse AD model</td>
</tr>
<tr>
<td class="label">Campisi et al. (2019)</td>
<td>Mouse aging</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Dose Range</td>
</tr>
<tr>
<td class="label">Topical</td>
<td>0.5-2% solution</td>
</tr>
<tr>
<td class="label">Subcutaneous</td>
<td>1-2 mg</td>
</tr>
<tr>
<td class="label">Intranasal (research)</td>
<td>0.5-1 mg</td>
</tr>
<tr>
<td class="label">Oral</td>
<td>2-5 mg</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Copper supplements</td>
<td>Potential copper overload</td>
</tr>
<tr>
<td class="label">Chelators (EDTA)</td>
<td>May reduce GHK-Cu efficacy</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>Potential synergy</td>
</tr>
</table>
Path: /therapeutics/ghk-cu Also Known As: Copper tripeptide, GHK-Cu, GHK-Copper Chemical Formula: C_14H_24N_6O_4Cu Sequence: Gly-Lys-Lys (with Cu²⁺ ion) Molecular Weight: ~403 Da (peptide), ~466 Da (with copper)
Overview
GHK-Cu is a naturally occurring copper-binding tripeptide discovered in human plasma in 1973. It plays important roles in tissue repair, inflammation modulation, and cellular signaling. The peptide's ability to bind copper makes it a crucial factor in copper-dependent enzymatic processes.
Mechanism of Action
1. Copper Delivery and Enzymatic Cofactor
- Copper transport: GHK delivers copper ions to cells in a regulated manner[@pickart2013]
- Enzyme activation: Serves as cofactor for copper-dependent enzymes including:
- Lysyl oxidase (cross-links collagen and elastin)[@rojkind1995]
- Cu/Zn superoxide dismutase (antioxidant defense)[@fridovich1997]
- Cytochrome c oxidase (mitochondrial energy)[@kadenbach2000]
2. Anti-Inflammatory Effects
- Modulates cytokine expression: Reduces pro-inflammatory TNF-α, IL-6 while enhancing anti-inflammatory IL-10[@miller2018]
- Inhibits NF-κB pathway: Prevents inflammatory gene transcription[@simpson2020]
- Reduces oxidative stress: Enhances antioxidant enzyme expression[@luo2021]
3. Tissue Regeneration
- Stimulates collagen synthesis: Increases collagen I and III production in fibroblasts[@maquart1990]
- Promotes angiogenesis: Upregulates VEGF expression for blood vessel formation[@sivaraman2018]
- Accelerates wound healing: Multiple mechanisms including fibroblast migration, keratinocyte proliferation[@pickart2016]
4. Anti-Aging and Cellular Senescence
- Senolytic activity: May help clear senescent cells[@lee2019]
- Telomere protection: Some evidence suggests telomere length preservation[@barcena2018]
- Mitochondrial support: Improves mitochondrial function and reduces ROS[@campisi2019]
5. Potential Neuroprotective Mechanisms
While CNS research is emerging, several mechanisms suggest neuroprotective potential:
- Copper homeostasis: Proper copper regulation is critical for neuronal function[@klis2021]
- SOD activation: Cu/Zn SOD protects neurons from oxidative damage[@tainer1996]
- Wound healing in CNS: May support repair processes in neural tissue[@hsu2022]
- Neurotrophic effects: Some studies suggest NGF and BDNF modulation[@mochizuki2010]
Evidence in Neurodegenerative Disease
Preclinical Data
Clinical Evidence
Current status: Limited direct clinical trials in neurodegenerative disease. Most human data comes from:
- Cosmetic and dermatological applications[@pickart2015a]
- Wound healing studies[@ahmed2016]
- Anti-aging research[@van2020]
Dosing and Administration
Typical Dosing Protocols
Administration Considerations
- Topical: Most common form; well-absorbed through skin
- Subcutaneous: Better systemic availability
- Intranasal: Potential direct CNS delivery (investigational)
- Combination: Often used with BPC-157 for synergistic effects
- Copper content: Each GHK-Cu molecule binds one Cu²⁺ ion (~16% copper by weight)
Safety Profile
Adverse Effects
- Generally recognized as safe (GRAS) for topical use
- Oral/subcutaneous: Limited data, but no significant toxicity in animal studies
- Possible: Mild skin irritation (topical), transient redness
Contraindications
- Wilson's disease (copper metabolism disorder)
- Active copper allergy
- Pregnancy/breastfeeding (insufficient data)
Drug Interactions
Relevance to CBS/PSP Patient
Potential Benefits
Case For
- Excellent safety profile, especially topically
- Multiple mechanisms complement other therapies
- Addresses copper homeostasis (declines with age)
- Easily accessible as topical/oral supplement
- Synergistic with BPC-157
Case Against
- No direct clinical evidence in tauopathies
- Limited long-term human safety data for systemic use
- Not FDA-approved for neurodegenerative indications
- Quality varies by manufacturer
Net Assessment
Priority: Consider — Low-risk adjunct therapy with favorable safety profile. The antioxidant and anti-inflammatory mechanisms are relevant to tauopathy pathology. Recommend topical application as first approach (better safety data), with subcutaneous as option if tolerated. May provide modest benefits as part of comprehensive treatment approach.
Confidence: Low — Strong mechanistic rationale, limited but growing preclinical evidence, human safety data good but not from neurodegenerative disease trials.
Research Gaps and Future Directions
Related Pages
- [BPC-157](/therapeutics/bpc-157) — Often stacked with GHK-Cu
- [Copper metabolism](/mechanisms/copper-homeostasis) — Related pathway
- [Oxidative stress](/mechanisms/oxidative-stress-neurodegeneration) — Related mechanism
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
Related Analyses:
- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
- [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
- [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-ghk-cu |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-425861628cba |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ghk-cu'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-ghk-cu?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[GHK-Cu — Copper-Binding Tripeptide](http://scidex.ai/artifact/wiki-therapeutics-ghk-cu)
http://scidex.ai/artifact/wiki-therapeutics-ghk-cu